Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from KMDA

The pharma sector is poised for strong growth thanks to rising demand for personalized treatments, an aging population, advancements in pharma technology, and innovative approaches to drug discovery and manufacturing. Hence, investors could consider buying quality pharmaceutical stocks such as Zoetis (ZTS), Rigel Pharmaceuticals (RIGL), and Kamada (KMDA) with May…

StockNews.com

Contracts awarding work to private parties should not be cancelled without assigning reasons: SC

Supreme Court reserves judgement on contract cancellation, emphasizing private parties' right to reasons for termination.

The Hindu

Navigate to Success With These 4 Pharma Stocks to Buy

The pharmaceutical industry is expanding due to increased demand for healthcare products and technological advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Hypera (HYPMY), Eli Lilly (LLY) and Sanofi (SNY) might be ideal additions to your portfolio. Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Gems Driving Profits Now

The pharmaceutical industry is expected to expand rapidly in the coming years, driven by rising global medical needs and tech advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Voyager Therapeutics (VYGR) and OptiNose (OPTN) might be ideal additions to your portfolio. Read on.

StockNews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

3 Resilient Pharma Stocks to Buy This Week

Amid rising global medical needs and advancement in technology, the pharma industry is expected to witness robust growth in the coming years. Given this backdrop, resilient pharma stocks such as Spero Therapeutics (SPRO), GoodRx Holdings (GDRX) and Kamada (KMDA) might be solid buys now. Read on.

StockNews.com

3 Undervalued Pharma Stocks Worth Buying

With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

2 Pharma Stocks to Watch Like a Hawk

From innovative drug pipelines to innovative research, the pharma sector offers a vast array of investment opportunities. Thus it would be wise to keep an eye on quality stocks Ipsen S.A.(IPSEY) and Kamada (KMDA), which hold considerable potential. Read more….

StockNews.com

Earnings Preview For Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

Benzinga

5 Pharmaceutical Stocks Under $10 to Buy Right Now

Supportive federal policies to boost medical research and development, tech integration, and robust demand are factors that are expected to drive the long-term growth of the pharmaceutical industry. Thus, we think it could be wise to bet on quality pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Radius Health (RDUS), Assertio Holdings (ASRT),…

StockNews.com

Kamada: Q4 Earnings Insights

Kamada (NASDAQ:KMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview: Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

Organisations

Medical Pharmaceuticals

117 stories

NVS

74 stories

Medical – Pharmaceuticals

Assertio Holdings Inc

17 stories

Catalyst Pharmaceuticals Inc

16 stories

OPTN

15 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Disease

10,849 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United States

243,762 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.